Physician profile
Uri Guefen
NPI 1275646333
$78,810.19
in general payments reported to CMS, 2019-2025
35 companies · $3,046 in 2025
The $3,046 reported for 2025 was more than what 98% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $19K · 2021: $19K · 2022: $12K · 2023: $3,180 · 2024: $1,704 · 2025: $3,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,067 · Consulting Fee: $1,250 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $600 · Entertainment: $13.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,067.08 |
| Consulting Fee | $1,250.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $600.00 |
| Entertainment | $13.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32,423.48 | 2019-2025 | |
| Amgen INC. | $20,868.12 | 2019-2025 | Repatha, Evenity, Otezla |
| Amarin Pharma, INC. | $13,335.42 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $4,902.16 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boston Scientific Corporation | $1,419.16 | 2022-2025 | Versacross Access Solution, Farapulse, Watchman Flx |
| Novo Nordisk INC | $1,228.76 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $868.76 | 2019-2023 | Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $693.97 | 2021-2024 | |
| Abbott Laboratories | $617.16 | 2023-2025 | Aveir, Mitraclip, Jot Dx |
| Glaxosmithkline, LLC. | $317.65 | 2020-2023 | Shingrix, Arexvy |
| Lilly USA, LLC | $271.73 | 2020-2025 | Mounjaro, Trulicity |
| Merck Sharp & Dohme LLC | $256.30 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $242.23 | 2022-2025 | |
| Esperion Therapeutics, INC. | $210.60 | 2020-2022 | |
| Edwards Lifesciences Corporation | $179.02 | 2024 | Sapien 3 Ultra Resilia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $134.54 | 2019-2023 | Descovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.71 | 2021-2024 | |
| Nestle Healthcare Nutrition INC. | $85.25 | 2020-2021 | |
| Hologic Sales and Service, LLC | $76.83 | 2025 | Aptima |
| Pfizer INC. | $72.96 | 2019-2024 | |
| Viiv Healthcare Company | $57.46 | 2025 | Apretude |
| Regeneron Healthcare Solutions, INC. | $51.91 | 2019 | |
| Nevro Corp. | $49.12 | 2022 | |
| Sun Pharmaceutical Industries INC. | $45.83 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $41.82 | 2021 | |
| Irhythm Technologies, INC. | $37.34 | 2023 | Zio Xt Patch |
| Xeris Pharmaceuticals, INC. | $36.52 | 2021 | |
| Philips North America LLC | $36.13 | 2024-2025 | Extended Holter, (Ck7) Extended Holter |
| Sanofi-Aventis U.S. LLC | $34.21 | 2019-2021 | |
| Exact Sciences Corporation | $29.69 | 2024 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $22.57 | 2022 | |
| Genentech USA, INC. | $22.28 | 2022 | |
| Bausch Health US, LLC | $20.62 | 2022 | |
| Itamar Medical INC | $16.78 | 2022 | |
| Optos, INC. | $13.10 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uri Guefen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.